ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.